This study tested the hypothesis that PI-PLCβ1 is associated with myeloid differentiation and that its expression could be useful for predicting the response of MDS patients to azacitidine, as the clinical effect of epigenetic treatments is often detectable only after several cycles of therapy. To this end, PI-PLCβ1 was quantified on 70 MDS patients (IPSS risk: 13 Low, 20 Int-1, 31 Int-2, 6 High) at baseline and during the first 3 cycles of azacitidine. Results were then compared with the hematologic response, as assessed after the 6th cycle of azacitidine therapy. Overall, 60 patients completed 6 cycles of azacitidine, and for them, a clinical and molecular evaluation was possible: 37 of these patients (62%) showed a specific increase of P...
Myelodysplastic syndromes (MDS), clonal hematopoietic stem-cell disorders mainly affecting older adu...
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodys...
A inositide-dependent signaling exists in the nucleus. In this review we focused to the nuclear PI-P...
This study tested the hypothesis that PI-PLCβ1 is associated with myeloid differentiation and that i...
none9Phosphoinositide-specific phospholipase C (PI-PLC) beta1 is a key enzyme in nuclear signal tran...
The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in h...
Phosphoinositide-phospholipase C (PI-PLC) beta1 can be considered a specific target for demethylatin...
The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in h...
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterize...
The Myelodysplastic Syndromes (MDS) are a heterogeneous group of bone marrow disorders characterized...
Background. The use of hypomethylating agents significantly modified the therapeutic approach to MDS...
Inositide signalling pathways are involved in cell growth, differentiation and apoptosis and play a ...
Azacitidine, a DNA methyltransferase inhibitor currently used for the treatment of higher-risk myelo...
none15Introduction.: Azacitidine (AZA) is a DNA methyltransferase inhibitor currently approved for ...
Myelodysplastic syndromes (MDS), clonal hematopoietic stem-cell disorders mainly affecting older adu...
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodys...
A inositide-dependent signaling exists in the nucleus. In this review we focused to the nuclear PI-P...
This study tested the hypothesis that PI-PLCβ1 is associated with myeloid differentiation and that i...
none9Phosphoinositide-specific phospholipase C (PI-PLC) beta1 is a key enzyme in nuclear signal tran...
The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in h...
Phosphoinositide-phospholipase C (PI-PLC) beta1 can be considered a specific target for demethylatin...
The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in h...
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterize...
The Myelodysplastic Syndromes (MDS) are a heterogeneous group of bone marrow disorders characterized...
Background. The use of hypomethylating agents significantly modified the therapeutic approach to MDS...
Inositide signalling pathways are involved in cell growth, differentiation and apoptosis and play a ...
Azacitidine, a DNA methyltransferase inhibitor currently used for the treatment of higher-risk myelo...
none15Introduction.: Azacitidine (AZA) is a DNA methyltransferase inhibitor currently approved for ...
Myelodysplastic syndromes (MDS), clonal hematopoietic stem-cell disorders mainly affecting older adu...
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodys...
A inositide-dependent signaling exists in the nucleus. In this review we focused to the nuclear PI-P...